Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
Development
Contracts Management
Review Committees
Funding News |
Research
Anticonvulsant Screening
Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
(TBI) Research
Technology Transfer
Office
NINDS is part of the
National Institutes of
Health
The NINDS recently invited an independent committee to review and consider the data from the five-year, multi-site “Tissue Plasminogen Activator for Acute Ischemic Stroke” study, published by the NINDS r-TPA Stroke Study Group in The New England Journal of Medicine, December 14, 1995. The study represents the first treatment for acute ischemic stroke, and the therapeutic agent t-PA was approved by the FDA for this usage in June of 1996.
In recent months, public debate about the study findings has resulted in some discussion within the medical community about the appropriate use of this treatment for stroke. In answer to this, the NINDS asked that the committee “address whether there is concern that eligible stroke patients may not benefit from rt-PA given according to the protocol used in the (NINDS) trials, and whether any subgroup imbalances invalidate the trial as claimed by some of the critics.”
The committee is chaired by W. Michael O’Fallon, Ph.D., professor of Biostatistics, former chair at the Department of Health Sciences Research at the Mayo Clinic, in Rochester, Minnesota, and a recent past president of the American Statistical Association. Dr. O’Fallon chose the members of the committee, who represent an international cadre of physician-scientists with expertise in biostatistics, clinical medicine, cerebrovascular disease, neurology, and emergency medicine. None of the committee members has a connection with the previous published study or with the manufacturer of t-PA. (See roster of the committee members below.)
The committee has full access to the study data, will re-analyze the study, and hopes to report its findings by early spring. The NINDS looks forward to the group’s findings and the presentation of the data analysis at professional meetings and in the scientific literature.
Committee Roster
W. Michael O'Fallon, Ph.D., Chair
Professor of Biostatistics
Mayo Clinic
Timothy J. Ingall, M.B. B.S., Ph.D.
Associate Professor of Neurology
Cerebrovascular Diseases Center
Mayo Clinic Scottsdale
Professor Thomas A. Louis, Ph.D.
Department of Biostatistics
Johns Hopkins Bloomberg School of Public Health
Lewis R. Goldfrank, M.D.
Director, Emergency Medicine
Bellevue Hospital Center
Professor, Clinical Medicine and Surgery
New York University School of Medicine
Kjell Asplund, M.D., Ph.D.
Head, Department of Medicine
University Hospital
Umea, Sweden
Vicki Stover Hertzberg, Ph.D.
Associate Professor
Department of Biostatistics
Emory University
This content has been adapted from the original NINDS Notes publication. For the most up-to-date funding information, please visit the Funding Opportunities section of the NINDS web site. For the most recent information on NINDS studies, please visit the NINDS Patient Recruitment web site.